{"protocolSection":{"identificationModule":{"nctId":"NCT01321749","orgStudyIdInfo":{"id":"RIPC2011"},"organization":{"fullName":"Capital Medical University","class":"OTHER"},"briefTitle":"The Neuroprotective Effect of Remote Ischemic Preconditioning on Ischemic Cerebral Vascular Disease"},"statusModule":{"statusVerifiedDate":"2012-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-01"},"primaryCompletionDateStruct":{"date":"2011-12","type":"ACTUAL"},"studyFirstSubmitDate":"2011-03-23","studyFirstSubmitQcDate":"2011-03-23","studyFirstPostDateStruct":{"date":"2011-03-24","type":"ESTIMATED"},"resultsFirstSubmitDate":"2012-01-11","resultsFirstSubmitQcDate":"2012-03-30","resultsFirstPostDateStruct":{"date":"2012-04-25","type":"ESTIMATED"},"lastUpdateSubmitDate":"2012-03-30","lastUpdatePostDateStruct":{"date":"2012-04-25","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Ji Xunming","investigatorTitle":"Xuan Wu Hospital","investigatorAffiliation":"Capital Medical University"},"leadSponsor":{"name":"Capital Medical University","class":"OTHER"},"collaborators":[{"name":"National Natural Science Foundation of China","class":"OTHER_GOV"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This study is a prospective, randomized, single-center trial, designed to observe the effect of remote limb ischemic preconditioning on ischemic cerebral vascular disease."},"conditionsModule":{"conditions":["Cerebrovascular Disease"],"keywords":["ischemic cerebral vascular disease","stroke secondary prevention","remote ischemic preconditioning"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":196,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"RIPC+stroke secondary prevension","type":"EXPERIMENTAL","description":"Procedure/Surgery: Remote Ischemic Preconditioning (RIPC) The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.\n\nProcedure:stroke secondary prevention(Such as Antiplatelet therapy, Cholesterol-lowering therapymaintain blood pressure and blood sugar normal)","interventionNames":["Procedure: Remote ischemic preconditioning (RIPC)"]},{"label":"stroke secondary prevention","type":"NO_INTERVENTION","description":"Procedure:stroke secondary prevention(Such as Antiplatelet therapy, Cholesterol-lowering therapymaintain blood pressure and blood sugar normal)"}],"interventions":[{"type":"PROCEDURE","name":"Remote ischemic preconditioning (RIPC)","description":"The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.","armGroupLabels":["RIPC+stroke secondary prevension"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Blood Pressure and Heart Rates;","timeFrame":"at the time points of baseline and 1, 15 and 30 days after BLIPC treatment"},{"measure":"Plasma Biomarkers of Coagulation and Fibrinolysis","description":"blood samples were collected one hour after every times of BLIPC procedure ended, and assayed with the immuno-turbidimetry assay on the coagulation laboratory autoanalyzer","timeFrame":"the time points of baseline and 1, 15 and 30 days after BLIPC treatment"},{"measure":"Number of Patients Who Got New Brain Lesions","description":"We compared the number of patients who got new lesions in the Diffusion-weighted magnetic resonance imaging (DWI-MRI)","timeFrame":"300 days after treatment"}],"secondaryOutcomes":[{"measure":"The Time Point Until the First Stroke Recurrence,","description":"These patients underwent MRI/DWI at the time of first recurrence; patients without symptoms recurrence underwent follow-up MRI/DWI at 300 days.","timeFrame":"At the 300-day after the initial treatment"},{"measure":"Brain Perfusion Improvement Are Evaluated With SPECT and TCD","description":"Brain perfusion status were evalvated by SPECT SPECT scanning was performed using a dual headed rotating gamma camera at 30 minutes after intravenous 99mTc-ECD (25mCi) bolus injection and at 40 minutes after 18F -FDG bolus injection.","timeFrame":"300-day after treatment"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Patients with stroke or transient ischemic attack (TIA) within 180 days and the neurologic deficits were well matched to the territory of the stenosed artery, with intracranial arterial stenosis of at least 50% by angiography, at least 70% by ultrasound, or at least 70% by computed tomographic angiography (CTA) or magnetic resonance angiography (MRA)\n2. Age between 18 to 80 years old\n3. Trial of Org 10172 in Acute Stroke Treatment-1 (TOAST-1) subtype\n4. National Institutes of Health Stroke Scale (NIHSS) score 0-15, and Modified Rankin Scale (mRS) score 0-4.\n5. ABCD2 score between 6 to 7\n6. Stable vital signs, normal hepatic and renal functions,\n7. No hemorrhagic tendencies.\n\nExclusion criteria:\n\n1. Within 72 hrs of intra-artery or intravenous thrombolysis\n2. Intracranial hemorrhage or large area of cerebral infarction (more than 1/3 middle cerebral artery perfusion territory)\n3. Any soft tissue, orthopedic, or vascular injury, wounds or fractures in extremities which may pose a contraindication for application of the preconditioning cuffs\n4. Acute myocardial infarction\n5. Systolic blood pressure more than 200 mmHg after drug control\n6. Peripheral blood vessel disease\n7. Hematologic disease\n8. Severe hepatic and renal dysfunction\n9. Severe or unstable concomitant disease\n10. Cannot tolerate BLIPC or without informed consent\n11. Patients who did not complete the whole treatment procedure.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Xuanwu Hospital, Capital Medical University","city":"Xicheng District","state":"Beijing P.R.","zip":"100053","country":"China"}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"RIPC+Stroke Secondary Prevension","description":"Procedure/Surgery: RIPC The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.\n\nProcedure:stroke secondary prevention"},{"id":"FG001","title":"Stroke Secondary Prevention","description":"Procedure:stroke secondary prevention"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"51"},{"groupId":"FG001","numSubjects":"52"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"38"},{"groupId":"FG001","numSubjects":"30"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"22"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"11"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"4"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"RIPC+Stroke Secondary Prevension","description":"Procedure/Surgery: RIPC The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.\n\nProcedure:stroke secondary prevention"},{"id":"BG001","title":"Stroke Secondary Prevention","description":"Procedure:stroke secondary prevention"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"51"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"103"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"63"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"40"}]}]}]},{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"61","spread":"10.1"},{"groupId":"BG001","value":"60","spread":"9.4"},{"groupId":"BG002","value":"60.5","spread":"9.7"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"43"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"60"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"China","categories":[{"measurements":[{"groupId":"BG000","value":"51"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"103"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Blood Pressure and Heart Rates;","reportingStatus":"NOT_POSTED","timeFrame":"at the time points of baseline and 1, 15 and 30 days after BLIPC treatment"},{"type":"PRIMARY","title":"Plasma Biomarkers of Coagulation and Fibrinolysis","description":"blood samples were collected one hour after every times of BLIPC procedure ended, and assayed with the immuno-turbidimetry assay on the coagulation laboratory autoanalyzer","reportingStatus":"NOT_POSTED","timeFrame":"the time points of baseline and 1, 15 and 30 days after BLIPC treatment"},{"type":"PRIMARY","title":"Number of Patients Who Got New Brain Lesions","description":"We compared the number of patients who got new lesions in the Diffusion-weighted magnetic resonance imaging (DWI-MRI)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"300 days after treatment","groups":[{"id":"OG000","title":"RIPC+Stroke Secondary Prevension","description":"Procedure/Surgery: RIPC The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.\n\nProcedure:stroke secondary prevention"},{"id":"OG001","title":"Stroke Secondary Prevention","description":"Procedure:stroke secondary prevention"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"30"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.05","statisticalMethod":"Log Rank","ciPctValue":"5"}]},{"type":"SECONDARY","title":"The Time Point Until the First Stroke Recurrence,","description":"These patients underwent MRI/DWI at the time of first recurrence; patients without symptoms recurrence underwent follow-up MRI/DWI at 300 days.","reportingStatus":"NOT_POSTED","timeFrame":"At the 300-day after the initial treatment"},{"type":"SECONDARY","title":"Brain Perfusion Improvement Are Evaluated With SPECT and TCD","description":"Brain perfusion status were evalvated by SPECT SPECT scanning was performed using a dual headed rotating gamma camera at 30 minutes after intravenous 99mTc-ECD (25mCi) bolus injection and at 40 minutes after 18F -FDG bolus injection.","reportingStatus":"NOT_POSTED","timeFrame":"300-day after treatment"}]},"adverseEventsModule":{"frequencyThreshold":"2.6","eventGroups":[{"id":"EG000","title":"RIPC+Stroke Secondary Prevension","description":"Procedure/Surgery: RIPC The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.\n\nProcedure:stroke secondary prevention","seriousNumAffected":0,"seriousNumAtRisk":51,"otherNumAffected":3,"otherNumAtRisk":51},{"id":"EG001","title":"Stroke Secondary Prevention","description":"Procedure:stroke secondary prevention","seriousNumAffected":0,"seriousNumAtRisk":52,"otherNumAffected":0,"otherNumAtRisk":52}],"otherEvents":[{"term":"transient sporadic subcutaneous bleeding points","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":51},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true,"restrictiveAgreement":false},"pointOfContact":{"title":"Xunming Ji, M.D.,Ph.D.","organization":"XuanWu Hospital, Capital Medical University","email":"jixm70@hotmail.com , Jixm@ccmu.edu.cn","phone":"8683198127"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000014652","term":"Vascular Diseases"}],"ancestors":[{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M11997","name":"Neoplasm Metastasis","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","asFound":"Cerebrovascular Disease","relevance":"HIGH"},{"id":"M17090","name":"Vascular Diseases","asFound":"Vascular Disease","relevance":"HIGH"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]}},"hasResults":true}